Business
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, in combination with ASC31, its in-house developed GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual targeting peptide agonist drug candidate.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model.","length":257,"tagName":"p"},{"type":"text","content":"- Combination of a low dose of ASC47 with ASC31 demonstrated statistically significantly greater efficacy than a combination of a low dose of ASC47 with tirzepatide, 44.8% compared to 38.1%, respectively, in the DIO mouse model.","length":234,"tagName":"p"},{"type":"text","content":"HONG KONG, Aug. 17, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, in combination with ASC31, its in-house developed GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual targeting peptide agonist drug candidate.","length":395,"tagName":"p"},{"type":"text","content":"ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates as well as promising in vitro activities and in vivo efficacy in the diet-induced obese (DIO) mice. ASC31 is part of Ascletis' discovery efforts to apply its Ultra-Long-Acting Platform (ULAP) to in-house discovered novel subcutaneously (SQ) injectable peptides and oral peptides.","length":465,"tagName":"p"},{"type":"text","content":"ASC47 is an adipose-targeted, once-monthly SQ injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.","length":330,"tagName":"p"},{"type":"text","content":"The objective of the DIO mouse study was to compare efficacy in weight loss of a low dose of ASC47 (9 mg/kg, SQ) combined with ASC31 (3 nmol/kg, SQ) to a low dose of ASC47 (9 mg/kg, SQ) combined with tirzepatide (3 nmol/kg, SQ). The treatment duration was 14 days. Results showed that the combination of ASC47 with ASC31 was 17.6% more effective (p=0.02) compared to the combination of ASC47 with tirzepatide,...